Careers  |  Sign In  |  Register

New Comprehensive Gene Test May Lead to Better Cancer Treatment

Reuters reports that “National Cancer Institute, Amgen Inc, AstraZeneca Plc and its U.S.-based biotech arm MedImmune, Roche’s Genentech unit and Pfizer Inc.” will partner together to begin clinical trials using a new comprehensive genetic test for cancer.” Current tests, known as companion diagnostics “look for a specific biological trait or ‘biomarker'” and the presence of these biomarkers can determine whether certain genetic therapies will work on particular tumor types. “Results of these broader tests could even be used to quickly identify which patients might benefit from experimental drugs being tested in clinical trials.”

Read the article published by Reuters.